MX2010001754A - Derivados de azepina como inhibidores de gamma secretasa. - Google Patents

Derivados de azepina como inhibidores de gamma secretasa.

Info

Publication number
MX2010001754A
MX2010001754A MX2010001754A MX2010001754A MX2010001754A MX 2010001754 A MX2010001754 A MX 2010001754A MX 2010001754 A MX2010001754 A MX 2010001754A MX 2010001754 A MX2010001754 A MX 2010001754A MX 2010001754 A MX2010001754 A MX 2010001754A
Authority
MX
Mexico
Prior art keywords
gamma
secretase inhibitors
azepine derivatives
azepine
derivatives
Prior art date
Application number
MX2010001754A
Other languages
English (en)
Spanish (es)
Inventor
Melina Joy Hope Miller
Warren Jaye Porter
Jon Kevin Reel
Almudena Rubio-Esteban
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2010001754A publication Critical patent/MX2010001754A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/12—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2010001754A 2007-08-14 2008-08-04 Derivados de azepina como inhibidores de gamma secretasa. MX2010001754A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95572007P 2007-08-14 2007-08-14
PCT/US2008/072049 WO2009023453A1 (en) 2007-08-14 2008-08-04 Azepine derivatives as gamma-secretase inhibitors

Publications (1)

Publication Number Publication Date
MX2010001754A true MX2010001754A (es) 2010-05-14

Family

ID=39811736

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010001754A MX2010001754A (es) 2007-08-14 2008-08-04 Derivados de azepina como inhibidores de gamma secretasa.

Country Status (11)

Country Link
US (1) US8188069B2 (OSRAM)
EP (1) EP2178844A1 (OSRAM)
JP (1) JP5385904B2 (OSRAM)
KR (1) KR101136260B1 (OSRAM)
CN (1) CN101778826B (OSRAM)
AU (1) AU2008287124B2 (OSRAM)
BR (1) BRPI0815135A2 (OSRAM)
CA (1) CA2694209C (OSRAM)
EA (1) EA017286B1 (OSRAM)
MX (1) MX2010001754A (OSRAM)
WO (1) WO2009023453A1 (OSRAM)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008076556A2 (en) 2006-11-15 2008-06-26 Massachusetts Eye & Ear Infirmary Generation of inner ear cells
JP5809061B2 (ja) 2008-11-24 2015-11-10 マサチューセッツ・アイ・アンド・イア・インファーマリー 有毛細胞を産生するための経路
TWI530489B (zh) 2011-03-22 2016-04-21 必治妥美雅史谷比公司 雙（氟烷基）－１，４－苯二氮呯酮化合物
US20130060023A1 (en) * 2011-09-07 2013-03-07 Satori Pharmaceuticals, Inc. Compounds useful for treating neurodegenerative disorders
JP2015527398A (ja) 2012-09-07 2015-09-17 マサチューセッツ アイ アンド イヤー インファーマリー 聴覚喪失治療
CN104869987B (zh) 2012-09-07 2020-10-16 麻省眼耳医院 用于再生毛细胞和/或支持细胞的方法及组合物
CN104822677A (zh) 2012-09-21 2015-08-05 百时美施贵宝公司 氟烷基-1,4-苯并二氮杂*酮化合物
EP2897960B1 (en) 2012-09-21 2016-08-03 Bristol-Myers Squibb Company Tricyclic heterocyclic compounds as notch inhibitors
US9427442B2 (en) 2012-09-21 2016-08-30 Bristol-Myers Squibb Company Fluoroalkyl and fluorocycloalkyl 1,4-benzodiazepinone compounds
TWI614238B (zh) 2012-09-21 2018-02-11 必治妥美雅史谷比公司 雙（氟烷基）－１，４－苯并二氮呯酮化合物及其前藥
CN104854094A (zh) 2012-09-21 2015-08-19 百时美施贵宝公司 氟烷基二苯并二氮杂*酮化合物
WO2014047391A1 (en) 2012-09-21 2014-03-27 Bristol-Myers Squibb Company Prodrugs of 1,4-benzodiazepinone compounds
US9187434B2 (en) 2012-09-21 2015-11-17 Bristol-Myers Squibb Company Substituted 1,5-benzodiazepinones compounds
US9242940B2 (en) 2012-09-21 2016-01-26 Bristol-Myers Squibb Company N-substituted bis(fluoroalkyl)-1,4-benzodiazepinone compounds
US9242941B2 (en) 2012-09-21 2016-01-26 Bristol-Myers Squibb Company Alkyl, fluoroalkyl-1,4-benzodiazepinone compounds
US9492469B2 (en) 2013-04-04 2016-11-15 Bristol-Myers Squibb Company Combination therapy for the treatment of proliferative diseases
WO2015073524A1 (en) * 2013-11-12 2015-05-21 Drexel University Novel methods of treating or preventing alzheimer's disease
WO2016022776A2 (en) 2014-08-06 2016-02-11 Massachusetts Eye And Ear Infirmary Increasing atoh1 life to drive sensorineural hair cell differentiantion
WO2016069906A1 (en) 2014-10-29 2016-05-06 Massachusetts Eye And Ear Infirmary Efficient delivery of therapeutic molecules to cells of the inner ear
US11185536B2 (en) 2015-12-04 2021-11-30 Massachusetts Eye And Ear Infirmary Treatment of hearing loss by inhibition of casein kinase 1
JP7080173B2 (ja) 2016-01-29 2022-06-03 マサチューセッツ アイ アンド イヤー インファーマリー 内耳支持細胞の拡大および分化ならびにその使用法
RU2754452C2 (ru) 2016-04-12 2021-09-02 Эли Лилли Энд Компани Комбинированная терапия ингибиторами notch и pi3k/mtor для применения в лечении рака
CA3020875A1 (en) 2016-04-12 2017-10-19 Eli Lilly And Company Combination therapy with notch and cdk4/6 inhibitors for the treatment of cancer
CA3024424A1 (en) 2016-05-16 2017-11-23 The General Hospital Corporation Human airway stem cells in lung epithelial engineering
ES2904880T3 (es) 2016-05-20 2022-04-06 Lilly Co Eli Terapia combinada con inhibidores de Notch y de PD-1 o PD-L1
WO2018071307A1 (en) 2016-10-12 2018-04-19 Eli Lilly And Company Targeted treatment of mature t-cell lymphoma
CA3047096A1 (en) 2016-12-16 2018-06-21 Pipeline Therapeutics, Inc. Methods of treating cochlear synaptopathy
MX2019009552A (es) 2017-02-17 2019-10-02 Hutchinson Fred Cancer Res Terapias de combinacion para el tratamiento de canceres relacionados con el antigeno de maduracion de celulas b (bcma) y trastornos autoinmunitarios.
US20200055948A1 (en) 2017-04-28 2020-02-20 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
EP3615068A1 (en) 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
CA3080395A1 (en) 2017-11-06 2019-05-09 Juno Therapeutics, Inc. Combination of a cell therapy and a gamma secretase inhibitor
EP3743057A4 (en) 2018-01-26 2021-11-17 Massachusetts Eye & Ear Infirmary TREATMENT OF HEARING LOSS
CN118459594A (zh) 2018-06-01 2024-08-09 诺华股份有限公司 针对bcma的结合分子及其用途
CN119679936A (zh) 2019-06-24 2025-03-25 诺华股份有限公司 针对靶向b细胞成熟抗原的多特异性抗体的给药方案和组合疗法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL158355A0 (en) * 1996-12-23 2004-05-12 Elan Pharm Inc CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS beta-AMYLOID PEPTIDE RELEASE INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
UA74849C2 (en) 2000-11-17 2006-02-15 Lilly Co Eli Lactam
US7468365B2 (en) 2000-11-17 2008-12-23 Eli Lilly And Company Lactam compound
TW200502221A (en) * 2002-10-03 2005-01-16 Astrazeneca Ab Novel lactams and uses thereof
JP2006520396A (ja) * 2003-03-14 2006-09-07 アストラゼネカ・アクチエボラーグ 新規なラクタム及びその使用

Also Published As

Publication number Publication date
AU2008287124B2 (en) 2013-06-06
US8188069B2 (en) 2012-05-29
WO2009023453A1 (en) 2009-02-19
JP5385904B2 (ja) 2014-01-08
JP2010536766A (ja) 2010-12-02
EA201070278A1 (ru) 2010-06-30
CN101778826B (zh) 2012-10-31
KR20100032924A (ko) 2010-03-26
EP2178844A1 (en) 2010-04-28
KR101136260B1 (ko) 2012-04-19
CN101778826A (zh) 2010-07-14
BRPI0815135A2 (pt) 2015-02-03
AU2008287124A1 (en) 2009-02-19
CA2694209A1 (en) 2009-02-19
US20100197660A1 (en) 2010-08-05
CA2694209C (en) 2013-09-17
EA017286B1 (ru) 2012-11-30

Similar Documents

Publication Publication Date Title
MX2010001754A (es) Derivados de azepina como inhibidores de gamma secretasa.
MX2009000884A (es) Derivados de piridizinona.
MY153915A (en) Organic compounds
MX2011005934A (es) Compuestos organicos.
GEP20156242B (en) 2-arylimidazole derivatives as pde10a enzyme inhibitors
AU2010246749A8 (en) Thiophene derivatives
MY147994A (en) Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors
AU2009236256A8 (en) Small molecule inhibitors of the pleckstrin homology domain and methods for using same
MY151986A (en) Adamantyl diamide derivatives and uses of same
SI2134691T1 (sl) Derivati kvinolina kot PARP in TANK inhibitorji
MX2012006805A (es) Indolil-piperidinil bencilaminas como inhibidores de beta-triptasa.
MX2012004780A (es) Inhibidores de akt.
EA201071224A1 (ru) Ингибиторы limk2, композиции, содержащие их, и способы их применения
TW200745084A (en) Novel compounds
TW200738653A (en) Anthranilamide/2-amino-heteroarene carboxamide derivatives
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
MX2010009022A (es) Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso.
UA99787C2 (en) Lactams as beta secretase inhibitors
TN2011000207A1 (en) Akt and p70 s6 kinase inhibitors
TW200738627A (en) Trialkylsilyl-indoles
SG158091A1 (en) Imidazoazepinone compounds
MX2010004604A (es) Derivados de pirazol como inhibidores de 5-lo.
PL1877367T3 (pl) Pochodne acetylenu
MX2012007253A (es) Derivados triciclicos y sus usos y composiciones farmaceuticas.
MX2009013667A (es) Inhibidores triciclicos de hidroxiesteroide deshidrogenasas.

Legal Events

Date Code Title Description
FG Grant or registration